CTLA4 and neoplasm: In 2017, a study of integrated molecular analysis of tumor biopsies, demonstrated that high burden of copy number loss was associated with disease progression despite sequential CTLA-4 blockade, and PD-1 blockade, compared with those biopsies from patients who responded to CTLA-4 blockade [67].